Amicus Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020
Amicus Therapeutics (Nasdaq: FOLD) will host a conference call on August 10, 2020, at 8:30 a.m. ET to discuss its financial results for Q2 2020, which ended June 30, 2020. CEO John F. Crowley and the senior leadership team will lead the call. Investors can participate by dialing designated numbers or accessing it via a live audio webcast on the company's investor website. A replay will be available for seven days post-event. Amicus focuses on developing innovative medicines for rare metabolic diseases.
- None.
- None.
CRANBURY, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2020.
The call will be led by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus senior leadership team. Interested participants and investors may access the conference call by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international), conference ID: 4949075.
A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call.
A replay of the call will be available for seven days beginning at 11:30 a.m. ET. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); conference ID: 4949075.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.
CONTACT:
Amicus Therapeutics
Andrew Faughnan
Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
FOLD–G
FAQ
When is the Amicus Therapeutics conference call?
How can I access the Amicus Therapeutics conference call?
What will be discussed during the conference call?
Will there be a replay of the conference call?
What is the stock symbol for Amicus Therapeutics?
